Mukul Agrawal gains Rs 32,14,40,000 & Vijay Kedia gains 10,45,98,000 from this multibagger pharma stock; Jumps over 6 per cent on July 09

On Wednesday, one of the Top Gainers on BSE & NSE, shares of this multibagger pharma company jumped over 6 per cent to Rs 12,479.05 per share from its previous closing of Rs 11674.45 per share. The stock’s 52-week high is Rs 18,089.55 per share while its 52-week low is Rs 7,662 per share. The shares of the company saw a spurt in volume by more than 3 times.

Two ace investors, Vijay Kedia and Mukul Agrawal, own 1.01 per cent (1,30,000 shares) and 3.12 per cent (4,00,000 shares) stake in the company, respectively, as of March 2025. Therefore, at the day’s high, Mukul Agrawal gained Rs 32,14,40,000 and Vijay Kedia gained 10,45,98,000.

The stock name is Neuland Laboratories Ltd.

About the Company

Neuland Labs, a pioneer in API manufacturing, has been serving customers in nearly 80 countries for over four decades. With a strong focus on quality and compliance, they have developed and manufactured over 300 processes and 100 APIs. Their commitment to regulatory excellence is evident in their 978+ regulatory filings across major markets like the US, EU, and others. Their manufacturing facilities, inspected and approved by leading regulatory agencies such as the US FDA, adhere to stringent cGMP standards, ensuring product quality and safety. This robust track record, backed by certifications from various regulatory bodies worldwide, solidifies Neuland Labs' position as a trusted partner in the pharmaceutical industry.

The company has a market cap of over Rs 15,000 crore with a PE of 74x, an ROE of 15 per cent and an ROCE of 19 per cent. The stock gave multibagger returns of 290 per cent in 2 years, 775 per cent in 3 years and a whopping 2,000 per cent in 5 years.

Do you own shares of Neuland Laboratories Ltd in your portfolio? Do let us know in the comments below

Disclaimer: The article is for informational purposes only and not investment advice.